Modern approaches to the prevention of frequent respiratory infections in childhood DOI Creative Commons
I. M. Melnikova,

Ю Л Мизерницкий

Meditsinskiy sovet = Medical Council, Journal Year: 2024, Volume and Issue: 19, P. 79 - 86

Published: Nov. 25, 2024

In recent decades, there has been significant progress in the diagnosis, prevention and treatment of acute respiratory viral infections (ARVI), including influenza. The authors summarized current literature data regarding clinical effectiveness antiviral immunomodulatory drug inosine pranobex frequent recurrent children. results studies have shown that during COVID-19 pandemic, non-drug restrictive measures influenced typical seasonal patterns circulation various viruses bacteria. Continuous monitoring these is necessary to take preventive improve forecasting, particular, optimize use drugs, especially among children with episodes SARS, as well those at risk their severe course. Resistance pathogens can be achieved by specific vaccination (against influenza, pertussis, pneumococcal, hemophilic infection, etc.), introduction immunoglobulins, monoclonal antibodies (for syncytial virus (RSV) infection). However, highly pathogenic virulent (influenza, SARS-CoV-2) its limitations due high variability viruses. Therefore, focus therapeutic against ARVI increasingly shifting towards non-specific based on safe effective drugs prevent development disease same time affect course, ensuring a favorable outcome. One choice ARI pranobex, burdened premorbid background cases where complex action required. absence effect for 3 months, an in-depth examination child polyclinic or hospital individual selection appropriate are shown.

Language: Английский

Rethinking Paediatric Respiratory Infections: The Role of Mixed Pathogen Infections DOI

Jinjin Wang,

Ran Wang,

Zhengde Xie

et al.

Reviews in Medical Virology, Journal Year: 2025, Volume and Issue: 35(2)

Published: Feb. 25, 2025

ABSTRACT Acute respiratory infections (ARIs) stand as a significant cause of morbidity and mortality among children worldwide, contributing substantially to paediatric hospitalisation rates. ARIs stem from various pathogens, including bacteria, viruses, others. With the advent novel diagnostic techniques like molecular detection methods, identification rate multiple pathogens in is steadily rising. However, there currently no consensus on impact mixed severity children. This narrative review summarises existing research indicating that co‐detection viruses patients with ranged 0.07% 55%. Multi‐virus coinfections did not appear increase disease because viral interference, immune modulation, etc. Conversely, infection virus bacteria may exacerbate through many mechanisms, such synergistic activation inflammation, diminished repair efficiency, increased transmission release so on. The insights provide aim improve precision treatment strategies for ARIs, ultimately reducing complications rates associated

Language: Английский

Citations

0
Modern approaches to the prevention of frequent respiratory infections in childhood DOI Creative Commons
I. M. Melnikova,

Ю Л Мизерницкий

Meditsinskiy sovet = Medical Council, Journal Year: 2024, Volume and Issue: 19, P. 79 - 86

Published: Nov. 25, 2024

In recent decades, there has been significant progress in the diagnosis, prevention and treatment of acute respiratory viral infections (ARVI), including influenza. The authors summarized current literature data regarding clinical effectiveness antiviral immunomodulatory drug inosine pranobex frequent recurrent children. results studies have shown that during COVID-19 pandemic, non-drug restrictive measures influenced typical seasonal patterns circulation various viruses bacteria. Continuous monitoring these is necessary to take preventive improve forecasting, particular, optimize use drugs, especially among children with episodes SARS, as well those at risk their severe course. Resistance pathogens can be achieved by specific vaccination (against influenza, pertussis, pneumococcal, hemophilic infection, etc.), introduction immunoglobulins, monoclonal antibodies (for syncytial virus (RSV) infection). However, highly pathogenic virulent (influenza, SARS-CoV-2) its limitations due high variability viruses. Therefore, focus therapeutic against ARVI increasingly shifting towards non-specific based on safe effective drugs prevent development disease same time affect course, ensuring a favorable outcome. One choice ARI pranobex, burdened premorbid background cases where complex action required. absence effect for 3 months, an in-depth examination child polyclinic or hospital individual selection appropriate are shown.

Language: Английский

Citations

0